Adoptive cell therapy (ACT), the autologous or allogenic transplant of immune cells, is providing new hope in the ongoing battle against cancer. However, the path to harnessing the full potential of these therapies remains challenging, from understanding the intricate dynamics of individual cells to optimizing their therapeutic efficacy. Bruker’s Beacon® Platform emerges as a transformative …
Cellular Analysis Blog
Explore T Cell Profiling Articles
Latest
Bruker Cellular Analysis’ Beacon® Platform Used to Characterize Engineered T Cell Products Specific for Fibrolamellar Carcinoma
In a new publication in Cell Reports Medicine from researchers at St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center (UTHSC), researchers used Bruker Cellular Analysis’s Beacon® Platform to validate the functional performance of engineered T cells generated to combat fibrolamellar carcinoma (FLC) by recognizing cancer-specific fusion proteins. The study used …
Revealing the Power of T Cells in the Fight Against Head and Neck Cancer with Bruker’s Cutting-Edge Platforms
Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) has remained challenging to treat, particularly due to its resistance to conventional therapies and limited response to immunotherapy. However, a recent study conducted by researchers at the Medical College of Wisconsin sheds new light on a potential breakthrough in this arena. Their findings, published in …
Neoantigens Unveiled: Revolutionizing Cancer Immunotherapy with Optofluidic Technology
Neoantigens are self-antigens that arise in tumor cells as a result of tumor-specific alterations commonly caused by genomic mutations. Due to their high immunogenicity and foreign nature, they have emerged as promising targets for cell-based cancer therapeutics. While advances in next-generation sequencing, bioinformatics technologies, and machine learning algorithms have greatly accelerated neoantigen prediction, only a …
Neoantigens Unveiled: Revolutionizing Cancer Immunotherapy with Optofluidic Technology Read More »
Unlock the Phenome